Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311885 | 0.87 | CYP11B1 (0.48) | CYP11B1CYP11B2SMN1; SMN2GAAKMT2A | |
| SCHEMBL3275833 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL10926533 | 0.77 | NPSR1 (0.43) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL3978876 | 0.77 | CYP11B1 (0.41) | CYP11B1CYP11B2SMN1; SMN2GAAKMT2A | |
| SCHEMBL7981213 | 0.76 | CYP11B1 (0.73) | CYP11B1CYP11B2 | |
| SCHEMBL3978013 | 0.75 | CYP11B1 (0.41) | CYP11B1CYP11B2SMN1; SMN2GAAKMT2A | |
| SCHEMBL31332849 | 0.75 | CYP11B1 (0.44) | CYP11B1CYP11B2 | |
| SCHEMBL27782413 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL5657526 | 0.72 | CYP11B1 (0.42) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL859620 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | CYP17A1, CYP11B1, CYP46A1 | CYP11B1 2/4885CYP11B2 11/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.